Trial · NCT03259334
Results by group144
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 144
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinical Response Based on Total Mayo Score at Week 12 | Ontamalimab 75 mg | 97 | Participants | ||
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Placebo | At Week 4 | 13 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 25 mg | At Week 4 | 38 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 75 mg | At Week 4 | 47 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Placebo | At Week 8 | 23 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 25 mg | At Week 8 | 57 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 75 mg | At Week 8 | 62 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Placebo | At Week 12 | 22 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 25 mg | At Week 12 | 60 | Participants | |
| Number of Participants With Partial Mayo Score <=2 With no Individual Sub-score Greater Than (>) 1 at Weeks 4, 8, and 12 | Ontamalimab 75 mg | At Week 12 | 78 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Placebo | At Week 4 | 15 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Ontamalimab 25 mg | At Week 4 | 34 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Ontamalimab 75 mg | At Week 4 | 38 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Placebo | At Week 8 | 23 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Ontamalimab 25 mg | At Week 8 | 57 | Participants | |
| Number of Participants With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8 | Ontamalimab 75 mg | At Week 8 | 60 | Participants | |
| Number of Participants With Endoscopic Remission With Sub-score of 0 at Week 12 | Placebo | 9 | Participants | ||
| Number of Participants With Endoscopic Remission With Sub-score of 0 at Week 12 | Ontamalimab 25 mg | 10 | Participants | ||
| Number of Participants With Endoscopic Remission With Sub-score of 0 at Week 12 | Ontamalimab 75 mg | 22 | Participants | ||
| Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Sub-scores of 0 at Weeks 4, 8, and 12 | Placebo | At Week 4 | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03259334/results?page=2